US Drug Recall Register
Class II · Moderate risk Ongoing Initiated Nov 14, 2024 (2 years ago)

Duloxetine Delayed-Release Capsules

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit

What was recalled

Duloxetine Delayed-Release Capsules, USP, 30 mg, Rx only, a) 30 count (NDC 68001-414-04) and b) 1,000 count (NDC 68001-414-08) bottles, Manufactured by: Aurobindo Pharma Limited, Hyderabad-500 090, India, For BluePoint Laboratories

Recalling firm
Amerisource Health Services LLC
NDC code
68001-414-04
Origin
OH, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0100-2025

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Duloxetine recalls

See all
Class II · Moderate risk Ongoing

Duloxetine D/R

Reason CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Direct Rx NDC 61919-482-30 D-0617-2026
Class II · Moderate risk Ongoing

Duloxetine Delayed-Release Capsules

Reason CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Breckenridge Pharmaceutical, Inc. NDC 51991-748-90 D-0583-2026
Class II · Moderate risk Ongoing

Duloxetine Delayed-Release Capsules

Reason CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Breckenridge Pharmaceutical, Inc. NDC 51991-747-10 D-0582-2026
Class II · Moderate risk Ongoing

Duloxetine DR Capsules

Reason CGMP Deviations; presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the FDA acceptable intake limit.

Asclemed USA Inc. NDC 76420-634-30 D-0555-2026
Class II · Moderate risk Ongoing

Duloxetine Delayed-Release Capsules

Reason CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals.

Ajanta Pharma Ltd. NDC 27241-097-06 D-0516-2026